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that condition) and increases the mortality probability as time progresses (reﬂecting 
patients that entered the trial with less severe and undetected cases of the condition 
or who developed the condition during the trial). Mortality was phased-in for four 
conditions reﬂective of their high prevalence and consistency with exclusion criteria: 
CHD, malignant neoplasms, chronic lower respiratory disease, and liver disease. 
RESULTS: To statistically compare the ACAS simulated versus actual mortality sur-
vival curves, we calculated the absolute differences between the curves and performed 
a standard equality of probabilities test on the curves at 12, 24, 36, 48, and 60 months. 
For the ACAS curve without mortality phase-in, at all times t before 60 months the 
simulated and actual curves had a statistically signiﬁcant difference (0 < p < 0.04). 
With mortality phase-in, there was no evidence at any time t that the simulated and 
actual curves had a statistically signiﬁcant difference (0.62 < p < 0.95). CONCLU-
SIONS: Phasing in mortality probabilities for trial-excluded conditions can simulate 
mortality survival curves that reﬂect the control arms of clinical trials.
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OBJECTIVES: It is well documented that standard logit regressions are biased in rare 
events. We wanted to illustrate how to analyze rare events in observational analysis 
using Medicare claims data. In particular, we compared the operational mortality for 
patients who underwent hip fracture surgery and suffered venous thromboembolism 
(VTE). METHODS: We applied two correction methods to address possible rare event 
bias. The ﬁrst method involved obtaining information about the fraction of those in 
the population and the observed fraction of those in the sample. We estimated the 
adjusted constant coefﬁcient in the logit model. In the second method, we weighted 
the proportion of ones and zeros in the sample to equal the true proportion in the 
population. We tested for differences in predicted probabilities using a non-parametric 
test. The Mann-Whitney U test and Kolmogorov-Smirnov two sample test can both 
be used on predicted probabilities of logit regression to see whether differences exist. 
RESULTS: To apply the methodology, we constructed a retrospective cohort study 
comparing the operational death rate between patients who underwent hip replace-
ment surgery who suffered VTE and patients who did not suffer VTE. 60,245 patients 
with hip fracture surgery were identiﬁed from the 100% Medicare Inpatient dataset. 
Mortality was rare (0.81% vs. 3.34% for patients with non-VTE vs. VTE). Using 
Monte Carlo simulation, the unadjusted rate was 0.97% for non-VTE patients and 
4.36% for VTE patients. The odds ratio was 3.98 for the standard model, 3.98 for 
the prior correction method, and 4.37 for the weighted mechanism. The predicted 
event probabilities were signiﬁcantly different. CONCLUSIONS: Standard logit 
regression is proven to underestimate probabilities with rare events. We examined two 
correction methods. The predicted event probabilities adjusted for rare event bias were 
signiﬁcantly different from the unadjusted ones.
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OBJECTIVES: The Comparative Effectiveness Index (CEI) provides a quantitative 
method of transforming efﬁcacy data into effectiveness indices. In lieu of head-to-head 
randomized controlled trials, the CEI uses efﬁcacy, adherence, and safety data to 
facilitate the drug evaluation process by providing a single value index for each thera-
peutic alternative. METHODS: Efﬁcacy data from clinical trials serve as surrogate 
markers of effectiveness. In analyzing two hypothetical anti-hypertensive drugs, A and 
B, the efﬁcacy of each drug is ranked on a nominal scale based on the literature: A = 
10 and B = 8. The drug with the highest nominal value is the most efﬁcacious. 
However, this value needs to be moderated by adherence and safety data. Adherence 
rates, calculated from claims databases for example, are: A = 60% and B = 90%. The 
formula for calculating the Modiﬁed Efﬁcacy Score (MES) of each drug is the (adher-
ence rate*efﬁcacy score)/100: A = 6 and B = 7.2. Adverse events (AE) reported in the 
clinical trials are ranked based on severity, the scale is anchored at 0 and 100 where 
0 = No AE and 100 = Death. Each AE is assigned a value depending on its severity 
then multiplied by the probability of its incidence. This is repeated for each AE and 
summed. The inverse of the sum, the Adverse Events Score (AES), is used in the ﬁnal 
computation so that both MES and AES modiﬁers have a direct relationship with the 
CEI. The AES for the drugs are: A = 3.33 and B = 5.00. The MES is multiplied by the 
AES to calculate the CEI. Consequently, the CEI would be: A = 19.98 and B = 36.00. 
Although drug A was more efﬁcacious, drug B is more effective. CONCLUSIONS: 
The CEI provides health care decision-makers with valuable comparisons between 
therapeutic alternatives, but it requires further development and validation. Incorpo-
rating measures of dispersion for efﬁcacy and compliance in a sensitivity analysis can 
generate more comprehensive indices.
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OBJECTIVES: Pediatric adverse drug events (ADEs) lead to substantial burden on 
patients, caregivers, and payers. The objective of the current study was to quantify 
the extent of the national pediatric ADE burden by determining (1 the frequency of 
ADE occurrence; (2 excess length of stay (LOS) and excess cost associated with 
hospitalization; and (3 the hospital, patient, and ADE characteristics that predict 
excess LOS and excess cost. METHODS: Using the 2006 Kids’ Inpatient Database, 
ADEs were identiﬁed using ICD-9 and supplemental Ecodes; ADE frequencies were 
computed. A hospitalization with an ADE was matched with 1 hospital visit without 
an ADE; matching criteria included the All Patient Reﬁned-Diagnosis Related Group, 
which accounts for severity of illness and risk of mortality, and gender and age. Excess 
LOS and excess cost (totals and means) were calculated for case-control pairs. An 
ordinary-least-squares regression was run, with the case-control pairs as observations, 
to determine signiﬁcant predictors of excess LOS and excess cost. RESULTS: In 2006, 
118,779 ADEs occurred in 99,320 visits out of 7,558,812 total pediatric hospitaliza-
tions. The mean excess LOS was 0.98 days (p < 0.0001), while the mean excess cost 
was $2,252 (p < 0.0001). Adverse effects from benzodiazepine-based tranquilizers, 
certain anticonvulsants, adrenal corticosteroids, and various antibiotics led to the 
highest excesses (all with p < 0.0001). The mean excess LOS and excess cost, respec-
tively, for neonates aged 0–7 days were 6.4 days (p < 0.0001) and $26,417 (p < 
0.0001). Statistically signiﬁcant predictors included age, hospital region, insurance 
coverage, hospital size, urban versus rural hospital location, major diagnostic category 
for hospital admission, and severity of illness. CONCLUSIONS: A substantial share 
of the pediatric ADE burden is accounted by adverse effects rather than accidental 
poisoning. Variation across regions, drug classes, and diagnoses suggests that efforts 
to reduce the ADE burden can be targeted to have the greatest impact.
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OBJECTIVES: The aim of the study is to determine the prevalence and use of poten-
tially inappropriate medication in elderly population according to the Beer’s criteria. 
METHODS: Data for the present study was obtained from National Nursing Home 
Survey (NNHS) 2004. Patients of the age 65 and above were taken as sample. The 
use of potentially inappropriate medication was assessed by ranking the rate of usage 
of the 48 medications listed in the Beer’s criteria that should be avoided in elderly 
patients and assessing the medication usage across demographics like gender and age. 
Descriptive statistics were carried out using SPSS 17. RESULTS: The total number of 
cases of the age 65 and above using the potentially inappropriate medication was 
2209. The top ﬁve most used drugs were ferrous sulfate ( 54.33%), Clonidine ( 7.8%), 
Lorazepam ( 6.9%), Biscodyl ( 6.9%) and Amioderone (5.7%). Other more used drugs 
were Nifedipine ( 2.6%), Amitryptyline ( 2.5%), Alprazolam (2.2%), Fluoxetine ( 
1.6%), Naprozen ( 1.4%), Temezepam (1.1%), Diazepam ( 0.95%) and Nitrofuroin-
toin (0.90%). The usage was more in female (73.7%) as compared to male (26.3%), 
it was more in the age group 85 to 100 ( 43.1%) compared to 65 to 74 ( 17.9%) and 
75 to 84 ( 39.1%). There were 2208 (91.8%) elders using at least one of the 48 medi-
cations and 181( 8.1%) elders using two of these 48 medications. CONCLUSIONS: 
The use of potentially inappropriate medication listed under Beer’s criteria is highly 
prevalent among the elderly. There is more usage in females compared to males and 
more in the age group 85 to 100. Among the top 12 drugs used, accept for Ferrous 
sulfate and Clonidine which has the low Beer’s severity rating, all other drugs have a 
high Beer’s severity rating and causes Adverse Drug Events.
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OBJECTIVES: To estimate the risks of gaining weight, with the use of selective 
serotonin reuptake inhibitors (SSRI) and atypical antipsychotics (SGA) in combination 
among children and adolescents. METHODS: A retrospective cohort study was con-
ducted using 2003–2005 Medicaid Analytic eXtract (MAX) data from four U.S. states. 
Combination pharmacotherapy was operationalized as the concurrent prescribing of 
SSRI and SGA, where at least 14 days of treatment overlap occurred. Long term 
combination use is deﬁned as an overlap beyond 60 days. Children and adolescents 
aged 6–18 years, and enrolled in Medicaid during 3 months prior and 1 year post the 
treatment initiation were selected. Multivariable logistic regression models were 
employed to estimate the risks of gaining weight during the one year follow up period. 
RESULTS: Among 118,126 children and adolescents received SSRI or SGA, 
56,091(12.5%) were on combination treatment and of which approximately 80% 
were on long-term therapy (>60 days). Vast majority (63%) of these recipients were 
